537 related articles for article (PubMed ID: 35639332)
21. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
[TBL] [Abstract][Full Text] [Related]
22. [Treatment for mantle cell lymphoma].
Izutsu K
Rinsho Ketsueki; 2017; 58(10):2026-2032. PubMed ID: 28978845
[TBL] [Abstract][Full Text] [Related]
23. Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors.
Burkart M; Karmali R
J Pers Med; 2022 Mar; 12(3):. PubMed ID: 35330376
[TBL] [Abstract][Full Text] [Related]
24. ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma.
Abramson JS; Ghosh N; Smith SM
Am Soc Clin Oncol Educ Book; 2020 May; 40():302-313. PubMed ID: 32421455
[TBL] [Abstract][Full Text] [Related]
25. Treatment Landscape of Relapsed/Refractory Mantle Cell Lymphoma: An Updated Review.
Al-Mansour M
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):e1019-e1031. PubMed ID: 36068158
[TBL] [Abstract][Full Text] [Related]
26. Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma.
Villa D; Jiang A; Visco C; Crosbie N; McCulloch R; Buege MJ; Kumar A; Bond DA; Paludo J; Maurer MJ; Thanarajasingam G; Lewis KL; Cheah CY; Baech J; El-Galaly TC; Kugathasan L; Scott DW; Gerrie AS; Lewis D
Blood Adv; 2023 Aug; 7(16):4576-4585. PubMed ID: 37307169
[TBL] [Abstract][Full Text] [Related]
27. Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma.
Li P; Dong N; Zeng Y; Liu J; Tang X; Wang J; Zhang W; Ye S; Zhou L; Chang AH; Liang A
Front Med; 2020 Dec; 14(6):811-815. PubMed ID: 32651937
[TBL] [Abstract][Full Text] [Related]
28. Treatment strategies in mantle cell lymphoma.
Maddocks K; Blum KA
Cancer Treat Res; 2015; 165():251-70. PubMed ID: 25655613
[TBL] [Abstract][Full Text] [Related]
29. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
[TBL] [Abstract][Full Text] [Related]
30. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.
Owen C; Berinstein NL; Christofides A; Sehn LH
Curr Oncol; 2019 Apr; 26(2):e233-e240. PubMed ID: 31043832
[TBL] [Abstract][Full Text] [Related]
31. Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?
Atilla E; Atilla PA; Demirer T
Int J Hematol; 2017 Mar; 105(3):257-264. PubMed ID: 27995456
[TBL] [Abstract][Full Text] [Related]
32. American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma.
Munshi PN; Hamadani M; Kumar A; Dreger P; Friedberg JW; Dreyling M; Kahl B; Jerkeman M; Kharfan-Dabaja MA; Locke FL; Shadman M; Hill BT; Ahmed S; Herrera AF; Sauter CS; Bachanova V; Ghosh N; Lunning M; Kenkre VP; Aljurf M; Wang M; Maddocks KJ; Leonard JP; Kamdar M; Phillips T; Cashen AF; Inwards DJ; Sureda A; Cohen JB; Smith SM; Carlo-Stella C; Savani B; Robinson SP; Fenske TS
Transplant Cell Ther; 2021 Sep; 27(9):720-728. PubMed ID: 34452722
[TBL] [Abstract][Full Text] [Related]
33. Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi.
Arcari A; Morello L; Vallisa D; Marcheselli L; Tecchio C; Quaglia FM; Tisi MC; Zilioli VR; Di Rocco A; Perrone T; Gini G; Dogliotti I; Bianchetti N; Bozzoli V; De Philippis C; Alvarez De Celis MI; Chiappella A; Fabbri A; Pelosini M; Merli M; Molinari AL; Sciarra R; Volpetti S; Hohaus S; Nassi L; Visco C
Leuk Lymphoma; 2021 Dec; 62(14):3474-3483. PubMed ID: 34625013
[TBL] [Abstract][Full Text] [Related]
34. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice.
Avivi I; Goy A
Clin Cancer Res; 2015 Sep; 21(17):3853-61. PubMed ID: 26059189
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
36. Pirtobrutinib: A novel non-covalent BTK inhibitor for the treatment of adults with relapsed/refractory mantle cell lymphoma.
Davis DD; Ohana Z; Pham HM
J Oncol Pharm Pract; 2024 Jan; 30(1):182-188. PubMed ID: 38043933
[TBL] [Abstract][Full Text] [Related]
37. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
Trněný M; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Afanasyev B; Kaplanov K; Thyss A; Kuzmin A; Voloshin S; Kuliczkowski K; Giza A; Milpied N; Stelitano C; Marks R; Trümper L; Biyukov T; Patturajan M; Bravo MC; Arcaini L;
Lancet Oncol; 2016 Mar; 17(3):319-331. PubMed ID: 26899778
[TBL] [Abstract][Full Text] [Related]
38. Novel therapies for relapsed/refractory mantle cell lymphoma.
Arora PC; Portell CA
Best Pract Res Clin Haematol; 2018 Mar; 31(1):105-113. PubMed ID: 29452660
[TBL] [Abstract][Full Text] [Related]
39. Cellular Therapies for Mantle Cell Lymphoma.
Yassine F; Sandoval-Sus J; Ayala E; Chavez J; Hamadani M; Kharfan-Dabaja MA
Transplant Cell Ther; 2021 May; 27(5):363-370. PubMed ID: 33965173
[TBL] [Abstract][Full Text] [Related]
40. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Wang M; Munoz J; Goy A; Locke FL; Jacobson CA; Hill BT; Timmerman JM; Holmes H; Jaglowski S; Flinn IW; McSweeney PA; Miklos DB; Pagel JM; Kersten MJ; Milpied N; Fung H; Topp MS; Houot R; Beitinjaneh A; Peng W; Zheng L; Rossi JM; Jain RK; Rao AV; Reagan PM
N Engl J Med; 2020 Apr; 382(14):1331-1342. PubMed ID: 32242358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
